She rocked the investors of public drug makers in India

The shares of Indian drug makers fell on Friday, although the American customs tariffs were 100 % on the patented and patented drug imports that are unlikely to affect these companies.

Sodershan Jain, official in the Indian Pharmaceutical Alliance, said that Indian companies are often exporting general medications to the United States, and therefore the potential effect will be minimal minimum.

However, the shares of the old Indian drug makers like Sen drugs and Devi laboratories It decreased by 2.5 % and 3.5 % on Friday, even with the standard NIFTy Pharma index in the sector by more than 2 %.

While investor fears may seem misplaced, Ayush Abhijit, the director of investment at White Oak Capital Partners, told the global market participants to see this as a series of events in the past two months.

“There was a set of challenges facing the economy of India,” Abigit said. Indicate 25 % American tariffs on Indiathen An additional tariff of 25 % Follow High H-1B visa fees.

Many of these definitions are not expected to be greatly affected by the economy or the erosion of the profits of Indian companies, but investors are afraid that there will be an additional escalation before trade relations in India improve.

Indian exporters of fabric, gemstones, jewelry and marine products were among the most affected by the definitions, but since the Indian economy Mostly paid Through special consumption, the effect of the limited tariff.

Last week, US President Donald Trump imposed a “one-time” visa fee of $ 100,000 on new H-1B visa requests, a step that can It affects inconsistently Indian workers.

Experts told CNBC experts that all of these ads in a quick caliphate make investors jazz, with a lot of escalation from Washington.

Gianundra Tebathi, a partner at BDO Partners, said there is a possibility that these successive moves by the United States will be part of the negotiating tactic to secure a faster trade deal with India.

Meanwhile, White Ok said, unlike textiles, as India lacks global competitiveness and its products can be replaced by exports from countries such as Bangladesh or Vietnam, and India has an advantage in the case of general medications.

“Even if () the United States is to impose a tariff on public Indian drugs, I will not be very concerned,” said Abhejit. He added: “The exporters of general medicines are able to compete and have few alternatives, so (A) a large part of the customs tariff will be transferred to the final mentors.”